Incyte's vision is to become a leading drug discovery and development company by building a proprietary product pipeline of novel small molecule drugs. We have an experienced team with prior success in bringing important new drugs to market. We believe we have the resources, experience and drive to improve the lives of patients and build sustainable value for our shareholders.
WILMINGTON, Del.--(BUSINESS WIRE)--Jan. 26, 2012--
Incyte Corporation (Nasdaq: INCY) announced today that it has scheduled
its fourth quarter/year-end 2011 financial results conference call for
8:30 a.m. ET on Wednesday, February 15, 2012. The schedules for the
press release and conference call are as follows:
-- Q4 & YE 2011 Press Release:
...
WILMINGTON, Del.--(BUSINESS WIRE)--Dec. 20, 2011--
Incyte Corporation (Nasdaq:INCY) announced today it will present at the
30th Annual J. P. Morgan Healthcare Conference on Monday,
January 9, 2012 at 8:30 a.m. (PT) / 11:30 a.m. (ET) in San Francisco.
The presentation will be webcast live and can be accessed at www.incyte.com
under Investor Relations, Events and Webcasts. A replay of the
presentation will be available for 90 days. Investors in...
Incyte to host a webcast for investors featuring these results on
Monday, December 12 at 7:00 p.m. PT
SAN DIEGO, Dec 12, 2011 (BUSINESS WIRE) --Incyte Corporation (Nasdaq:INCY) today announced that further analyses
from the global, pivotal Phase III clinical program of Jakafi
(ruxolitinib or INC424) are being presented at the 2011 American Society
of Hematology (ASH) Annual Meeting. The presentations include:
Verstovsek S, et al. Consistent benefit o...
Notice To Readers: Incyte's press releases, presentations and printed remarks are included on this Web site for historical purposes only. The information contained in these documents and webcasts should be considered accurate only as of the date of the relevant document or presentation. This information may change over time; therefore, visitors to this Web site should not assume that the information contained in these documents or presentations remains accurate at a later time. We do not have any current intention, and expressly disclaim any obligation, to supplement, update or revise any of the information in these documents or presentations.
Replication or redistribution of EDGAR Online, Inc. content is expressly prohibited without the prior written consent of EDGAR Online, Inc. EDGAR Online, Inc. shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.
Pamela M. Murphy VP, Investor Relations and Corporate Communications Experimental Station Route 141 & Henry Clay Road Building E336 Wilmington, DE 19880 302.498.6944 302.425.2707 pmurphy@incyte.com
